Stellate Ganglion Block to Augment Trauma-focused Therapy Among Veterans With PTSD

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Our long-term goal is to improve clinical outcomes among patients receiving psychological treatment for posttraumatic stress disorder (PTSD). The primary objective of this project is to examine if stellate ganglion block (SGB) improves outcomes among military personnel and veterans receiving cognitive processing therapy (CPT), an empirically-supported psychological treatment for PTSD. To accomplish this objective, we will enroll adult military personnel and veterans with a current diagnosis of PTSD and/or subthreshold PTSD, provide CPT sessions over two weeks, administer SGB during or after CPT, and repeatedly assess key outcomes during follow-up.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University
• Collaborators: Navy SEAL Foundation; The Stellate Institute

Criteria

Inclusion Criteria:

• 18 years of age or older

• Prior or current service in the U.S. military

• Diagnosis of PTSD within the last month

• Ability to speak and understand the English language

• Stable psychotropic medication dosing for at least 3 months

• Ability to complete the informed consent process

Exclusion Criteria:

• Prior SGB treatment or CPT treatment

• History of schizophrenia, another psychotic disorder, or bipolar disorder

• Moderate or severe traumatic brain injury

• Moderate or severe symptoms of a substance use disorder within the preceding 30 days

• Severe suicide risk warranting suicide-focused treatment and/or inpatient hospitalization

• Impaired mental status that precludes the ability to provide informed consent

• Any ongoing stressor or condition deemed by the investigators to place the participant at risk for injury or a poor outcome